Previous 10 | Next 10 |
home / stock / fbiop / fbiop news
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeu...
Journey Medical Corporation (FBIO) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Claude Maraoui - Co-Founder President and Chief Executive Officer Ernest De Paolantonio - Chief Financial Officer Ramsey Alloush - General Counsel ...
The market has shown strong support for Alexion YTD, where shareholders have enjoyed +64.28% since the selloff in March. Strong revenue growth on healthy margins paints the picture for periods to come, with equally as satisfying FCF positioning and capital structure. New level of ...
Myovant reports additional data from uterine fibroids study. Fortress Biotech reports start of AL Amyloidosis Phase 3 studies. Avita begins enrolment for vitiligo repigmentation pivotal study. For further details see: Myovant Reports Data, And Other News: The Good, Bad A...
The following slide deck was published by Fortress Biotech, Inc. in conjunction with this Read more ...
NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “the Company”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and deve...
NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-s...
The following slide deck was published by Fortress Biotech, Inc. in conjunction with this Read more ...
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential marketed and development-st...
Fortress Biotech ( FBIO ) has made significant progress since my 11/24/2018 article on the Fortress Biotech Inc. 9.375% Cum Conv Perp Red Pfd Registered Shs Series ( FBIOP ). Although FBIOP remains a speculative issue, it has appreciated in price from $17.58 to $20.00 since my last artic...
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Company Name:
FBIOP Stock Symbol:
NASDAQ Market:
2024-05-10 21:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-11 10:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-20 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...